Delivery Order SPE2DB20D3104-SPE2DB21FV8Y3
- Not listed
- This federal contract award is for pharmaceutical and medical supply distribution services provided by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, awarded by the Defense Logistics Agency (DLA), is a delivery order under a $999,999,999 Indefinite Delivery Contract (IDC) that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies,...
- This federal contract award is for pharmaceutical and medical supply services provided by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, awarded by the Defense Logistics Agency (DLA), is a delivery order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The IDC runs through November 2026 and covers a comprehensive range of pharmaceutical and medical commodities, including specialty medications, brand-name and generic...
- This federal contract award is from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a Delivery Order under DLA's Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, covers the supply of critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. This IDC serves as the...
- This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of a wide range of pharmaceutical products and medical supplies to the U.S. government. The award was made by the Defense Logistics Agency (DLA) through a Delivery Order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide essential medications,...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $23,281.60 and issued by the Defense Logistics Agency (DLA) under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The IDC, which runs through November 2026, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans'...
- This federal contract award is for pharmaceutical and medical supply delivery services provided by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, awarded by the Defense Logistics Agency (DLA), is a delivery order under a $999,999,999 Indefinite Delivery Contract (IDC) that runs through November 2026. The contract covers a wide range of pharmaceutical products and medical supplies, including specialty medications, generic drugs, brand-name pharmaceuticals, medical...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order under a Defense Logistics Agency (DLA) Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The IDC, which runs through November 2026, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare...
- This federal contract award is for a pharmaceutical prime vendor contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, awarded by the Defense Logistics Agency (DLA), is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 through November 2026. The contract covers the delivery of a comprehensive range of pharmaceutical products and medical supplies, including specialty medications,...
- This federal contract award is for pharmaceutical and medical supply delivery orders issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $9,157.72, is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., worth up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB21FV8Y3Delivery Order
This federal contract award is for pharmaceutical and medical supply delivery services provided by Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, awarded by the Defense Logistics Agency (DLA), is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract has a performance period through November 2026 and does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen's parent company, Cencora, Inc., also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 7/26/21 |